Daisuke Nishi1,2, Kenji Hashimoto2,3, Hiroko Noguchi1,2, Kei Hamazaki2,4, Tomohito Hamazaki2,5, Yutaka Matsuoka6,7. 1. Department of Psychiatry, National Disaster Medical Center, 3256 Midoricho, Tachikawa, Tokyo, 190-0014, Japan. 2. CREST, Japan Science and Technology Agency, 3256 Midoricho, Tachikawa, Tokyo, 190-0014, Japan. 3. Division of Clinical Neuroscience, Chiba University Center for Forensic Mental Health, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8670, Japan. 4. Department of Public Health, Faculty of Medicine, University of Toyama, 2630 Sugitani, Toyama, Toyama, 930-0194, Japan. 5. Toyama Jonan Onsen Daini Hospital, 1-13-6 Toromaru-nishimachi, Toyama, Toyama, 939-8271, Japan. 6. Department of Psychiatry, National Disaster Medical Center, 3256 Midoricho, Tachikawa, Tokyo, 190-0014, Japan. matsuoka-psy@umin.ac.jp. 7. CREST, Japan Science and Technology Agency, 3256 Midoricho, Tachikawa, Tokyo, 190-0014, Japan. matsuoka-psy@umin.ac.jp.
Abstract
RATIONALE: Accumulating evidence suggests involvement of the glutamatergic system in the biological mechanisms of posttraumatic stress disorder (PTSD), but few studies have demonstrated an association between glutamatergic system abnormalities and PTSD diagnosis or severity. OBJECTIVE: We aimed to examine whether abnormalities in serum glutamate and in the glutamine/glutamate ratio were associated with PTSD diagnosis and severity in severely injured patients at risk for PTSD and major depressive disorder (MDD). METHODS: This is a nested case-control study in TPOP (Tachikawa project for prevention of posttraumatic stress disorder with polyunsaturated fatty acid) trial. Diagnosis and severity of PTSD were assessed 3 months after the accidents using the Clinician-Administered PTSD Scale. The associations of glutamate levels and the glutamine/glutamate ratio with diagnosis and severity of PTSD and MDD were investigated by univariate and multiple linear regression analyses. RESULTS:Ninety-seven of 110 participants (88 %) completed assessments at 3 months. Serum glutamate levels were significantly higher for participants with full or partial PTSD than for participants without PTSD (p = 0.049) and for participants with MDD than for participants without MDD (p = 0.048). Multiple linear regression analyses showed serum glutamate levels were significantly positively associated with PTSD severity (p = 0.02) and MDD severity (p = 0.03). The glutamine/glutamate ratio was also significantly inversely associated with PTSD severity (p = 0.03), but not with MDD severity (p = 0.07). CONCLUSIONS: These findings suggest that the glutamatergic system may play a major role in the pathogenesis of PTSD and the need for new treatments targeting the glutamatergic system to be developed for PTSD.
RCT Entities:
RATIONALE: Accumulating evidence suggests involvement of the glutamatergic system in the biological mechanisms of posttraumatic stress disorder (PTSD), but few studies have demonstrated an association between glutamatergic system abnormalities and PTSD diagnosis or severity. OBJECTIVE: We aimed to examine whether abnormalities in serum glutamate and in the glutamine/glutamate ratio were associated with PTSD diagnosis and severity in severely injured patients at risk for PTSD and major depressive disorder (MDD). METHODS: This is a nested case-control study in TPOP (Tachikawa project for prevention of posttraumatic stress disorder with polyunsaturated fatty acid) trial. Diagnosis and severity of PTSD were assessed 3 months after the accidents using the Clinician-Administered PTSD Scale. The associations of glutamate levels and the glutamine/glutamate ratio with diagnosis and severity of PTSD and MDD were investigated by univariate and multiple linear regression analyses. RESULTS: Ninety-seven of 110 participants (88 %) completed assessments at 3 months. Serum glutamate levels were significantly higher for participants with full or partial PTSD than for participants without PTSD (p = 0.049) and for participants with MDD than for participants without MDD (p = 0.048). Multiple linear regression analyses showed serum glutamate levels were significantly positively associated with PTSD severity (p = 0.02) and MDD severity (p = 0.03). The glutamine/glutamate ratio was also significantly inversely associated with PTSD severity (p = 0.03), but not with MDD severity (p = 0.07). CONCLUSIONS: These findings suggest that the glutamatergic system may play a major role in the pathogenesis of PTSD and the need for new treatments targeting the glutamatergic system to be developed for PTSD.
Authors: Douglas F Zatzick; Joan Russo; Roger K Pitman; Frederick Rivara; Gregory Jurkovich; Peter Roy-Byrne Journal: Biol Psychiatry Date: 2005-01-01 Impact factor: 13.382
Authors: Adriana Feder; Michael K Parides; James W Murrough; Andrew M Perez; Julia E Morgan; Shireen Saxena; Katherine Kirkwood; Marije Aan Het Rot; Kyle A B Lapidus; Le-Ben Wan; Dan Iosifescu; Dennis S Charney Journal: JAMA Psychiatry Date: 2014-06 Impact factor: 21.596
Authors: Ryan E Tyler; Benjamin Z S Weinberg; Dennis F Lovelock; Laura C Ornelas; Joyce Besheer Journal: Genes Brain Behav Date: 2020-08-25 Impact factor: 3.449
Authors: Lynnette A Averill; Prerana Purohit; Christopher L Averill; Markus A Boesl; John H Krystal; Chadi G Abdallah Journal: Neurosci Lett Date: 2016-12-01 Impact factor: 3.046
Authors: Benjamin Kelmendi; Thomas G Adams; Stephanie Yarnell; Steven Southwick; Chadi G Abdallah; John H Krystal Journal: Eur J Psychotraumatol Date: 2016-11-08